Expanding successful business relationships in Middle-East

Consciously and in line with its expansion goals, Innov-Cell Therapeutics, a subsidiary of the IGHS Group, has been establishing proximity contacts with business groups consolidated in the Middle East. 
This constitutes a major opportunity to push Kelo.Cell brand’s positioning within geographies of a singular growth, in the pharmaceutical sector’s framework, to be added as another solid demonstration of recognition of the Portuguese group’s work on the global market.
The permanent challenge of establishing effective, long-lasting relationships between partners, in the continuity of transactions, is the DNA of a company that possesses a product like Kelo.Cell Biogel – clinically tested scar care formula, recommended by internationally renowned healthcare professionals.
Operations based on the ability to communicate, the quality and innovation of the product, in face of the outlined expansion project.

• Innov.Cell ended its successful participation in CPHI 2024

  Innov.Cell, a subsidiary of IGHS, ended its successful participation in CPHI 2024, which took place in Milan, with a positive outcome. This year, CPHI was attended by more than 62,000 people and around 2,400 exhibitors from 166 countries. Throughout the event, Innov.Cell met with several potential partners, from R&D, investors, and distributors covering more than 50 countries.

  Read more
• OIH Introduces Revolutionary Treatment for Keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS)

  Oman International Hospital is thrilled to announce the successful introduction of a groundbreaking procedure designed to treat keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS). This innovative treatment marks a significant advancement in ophthalmology, offering new hope to patients suffering from this debilitating corneal disorder.
   

  Read more